D. Boral Capital Reiterates “Buy” Rating for Turn Therapeutics (NASDAQ:TTRX)

Posted by ABMN Staff on Mar 26th, 2026

Turn Therapeutics (NASDAQ:TTRX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $8.00 target price on the stock. D. Boral Capital’s price target suggests a potential upside of 134.60% from the stock’s previous close.

Separately, Weiss Ratings started coverage on Turn Therapeutics in a report on Monday, January 5th. They set a “sell (e-)” rating on the stock. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

View Our Latest Stock Analysis on TTRX

Turn Therapeutics Stock Performance

TTRX opened at $3.41 on Tuesday. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50. The company’s fifty day moving average price is $3.82. The stock has a market cap of $100.41 million and a PE ratio of -48.71.

Institutional Trading of Turn Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Wellington Shields & Co. LLC purchased a new stake in shares of Turn Therapeutics during the 4th quarter worth approximately $259,000. HighTower Advisors LLC purchased a new position in shares of Turn Therapeutics in the fourth quarter valued at $78,000. RVW Wealth LLC purchased a new position in shares of Turn Therapeutics in the fourth quarter valued at $71,000. LPL Financial LLC bought a new stake in Turn Therapeutics in the fourth quarter worth $51,000. Finally, Brown Brothers Harriman & Co. bought a new stake in Turn Therapeutics in the fourth quarter worth $93,000.

About Turn Therapeutics

(Get Free Report)

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.